Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia

Neil Elliot Kay, Betsy R. LaPlant, Adam M. Pettinger, Timothy G. Call, Jose F. Leis, Wei D Ding, Sameer A Parikh, Michael J. Conte, Deborah A. Bowen, Tait D. Shanafelt

Research output: Contribution to journalArticle

6 Scopus citations


Background: 7 regimens of pentostatin based chemoimmunotherapy (CIT) for progressive previously untreated CLL primarily with long term follow-up to update both efficacy and toxicity. Research design and methods: Prognostic markers including assessment of IGVH and FISH status were done on all. Response rates and 95% binomial confidence intervals were calculated for each regimen and in the combined cohort. Overall survival and treatment-free survival were evaluated using Kaplan-Meier methods. Results: The initial CIT trial was pentostatin (2 mgs/m2), cyclophosphamide (600 mg/m2) and rituximab (PCR) but subsequent P based CIT trials with modifications in subsequent trials. The cohort (n = 288) included 52% with unmutated IGVH status and del17p (4.5%) and del11q (14.9%). Toxicity profiles were primarily hematologic and no patient has developed MDS or AML after a median follow-up of 6.4 years. The overall response rate across all trials was found to be over 90% with a 41% complete response rate. We validated that the CLL IPI model segregates progressive CLL patients into 4 risk groups associated with OS and TFS. Conclusions: The high overall and complete response levels in favorable genetic risk CLL along with favorable toxicity profiles provide rationale for consideration of a PC based strategy for previously untreated progressive CLL.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalExpert Review of Hematology
StateAccepted/In press - Feb 26 2018



  • chemoimmunotherapy
  • chronic lymphocytic leukemia
  • Pentostatin

ASJC Scopus subject areas

  • Hematology

Cite this